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SUMMARY 
 
Purpose: to evaluate acute toxicity of combined treatment (androgen ablation and high-dose 3D 
conformal radiotherapy [3D-CRT]) in patients with a localized cancer of prostate.  
Materials and methods: Between April 1999 and March 2000, at the Greatpoland Cancer Centre 
in Poznań, 22 patients with prostate cancer (T1-T3 N0 M0) were treated with 3 D conformal radiation 
therapy and hormonal therapy. Patients represented a localized disease (T1 = 4 patients, T2 = 11 
patients), and locally disease (T3 = 7 patients). No patients had clinically detectable distant 
metastases. Neoadjuvant androgen ablation therapy (bilateral orchiectomy or LH-RH agonists 
and flutamide) was administered to all patients. Radiotherapy was performed using 15 MV photons 
in the daily fraction of 1.8 Gy to the total median dose of 70.2 Gy (range, 67.8 to 72 Gy). Acute 
toxicities were evaluated according to the Radiation Therapy Oncology Group morbidity scoring scale. 
Results: All patients completed the entire course of radiotherapy and were assessable for evaluation 
of acute toxicities. The most common side effects of androgen ablation were “hot flushes” and gyneco-
mastia, although these were mild. The main problems during irradiation and a few weeks after 
the completion of radiotherapy were related to:  
- the genitourinary tract (urgency, nocturia, dysuria) with toxicities of grade 0 and 1 (80% of pa-
tients) and grade 2 (20% of patients), 
- the gastrointestinal tract (rectal discomfort and mild diarrhea) with toxicities grade 0 and 1 
(75% of patients) and grade 2 (25% of patients). 
Conclusions: Preliminary results of combined treatment (androgen ablation and 3 D-CRT) have 
suggested that such modality is well tolerated with only modest acute toxicities of the gastrointestinal 
and genitourinary tracts.  
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INTRODUCTION 
 
   The number of diagnosed cases of pro-
state cancer is on the increase in Poland 
(the incidence rate for 1993 was 13.7 per 
100.000 males and the mortality was 
10.3 per 100.000) [1]. The five-year 
survival patients with prostate cancer 
stands now at 37% and is among the lo-
west in European countries, where 
the average 5-year overall survival is 55% 
[2].  
   The role of radiotherapy in the treatment 
of localized prostate cancer is well esta-
blished, although there are still many 
controversies concerning its efficancy [3]. 
Three-dimensional conformal radiotherapy 
(3D-CRT) may lead to more favorable 
outcome in a localized stage of the cancer. 
For example, Hanks and al. [4] reported 
improvement of treatment outcomes from 
48% to 79% based on the PSA as an indi-
cator of biochemical relapse. Zelefsky 
et al. [5] with the increase in dose to 81 Gy, 
18 months after the completion of radio-
therapy achived normalisation of PSA 
in 99% of cases in T1/T2b stage, in 90% 
of cases in T2c stage and in 81% of cases
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in T3 stage. Since the 5-year, biochemical 
disease-free survival rate for 3D-CRT 
is similar to that for radical prostatectomy, 
early and late morbidities have become 
increasingly important in making decision 
concerning the treatment procedure.  
   Recently high-dose 3D conformal 
radiotherapy in conjunction with androgen 
depletion has been introduced at our de-
partment in an attempt to improve the re-
sults of treatment. The data from literature 
have shown that the outcome in patients 
treated with hormonal therapy and radio-
therapy (combined treatment) were signi-
ficantly better than radiotherapy treatment 
alone [6,7].  
 
PURPOSE 
 
   The aim of this study was to evaluate 
early toxicity of combined treatment: 
androgen ablation therapy (neoadjuvant, 
during irradiation and follow-up) and three-
dimensional conformal radiotherapy (3D-
CRT) in patients with prostate cancer. 
 
MATERIAL AND METHODS 
 
   Between April 1999 and March 2000, 
at the Greatpoland Cancer Centre 
in Poznań, 22 patients with prostate 
cancer (T1-T3N0M0) were treated with 
hormonal therapy and high-dose 3 D-CRT. 
The median age of patients was 68 years 
(range: 55-75 years). All patients had a 
histological diagnosis of prostate adeno-
carcinoma, but only some of patients were 
classified according to the Gleason 
scoring system. The average level of PSA 
before radiotherapy was 15 ng/ml (range, 
4 to 60 ng/ml). No patients had clinically 
detectable distant metastases (negative 
bone scan, chest X-ray – without change). 
All of them suffered from a localized organ 
limited disease (T1 = 4 patients, T2 = 11 pa-
tients), and locally disease (T3 = 7 pa-
tients) and had their lymph nodes evalu-
ated by computer tomography and ultraso-
nography. Only patients without any pa-
thology in these examinations were 
treated with 3 D-CRT. We did not perform 
diagnostic lymphadenectomy of the pelvic 
lymph nodes. When a high risk of lymph 
nodes metastases was suspected a large 
pelvic fields encompassing regional nodes 
were included in treatment planning. 
Neoadjuvant androgen ablation therapy 
(orchiectomy or LH-RH agonists and flu-
tamide) was administered to all patients. 
Orchiectomy was performed in 5 out of 22 
patients. During and after completion of ra-
diotherapy all patients received androgen 
depletion treatment (gosereline: 3.6mg/ 4 
weeks). An average time of androgen abla-
tion was 6 months (range: 3 to 12 months).  
   Simulation and treatment were perfor-
med in a supine position with a ”comfor-
table” full bladder. All patients had CT 
scanning of the pelvis in the treatment 
position. Images were obtained at 5 mm 
increments accross the treatment field. 
Patients were immobilized during simu-
lation and irradiation with the individually 
immobilization cast. Radiotherapy was 
administered using 15 MV photons 
in a daily fraction of 1.8 Gy to the total 
median dose of 70.2 Gy (range: 67.8 
to 72 Gy) prescribed at the isocenter 
(ICRU point). The planning target volume 
(PTV) was defined as the gross target 
volume and clinical target volume (GTV 
+ CTV): the prostate and the seminal 
vesicles with 10 mm margins around the 
prostate except for the posterior margin 
(prostate - rectum interface) where a mar-
gin about 5 mm was used to decrease 
the risk of rectum morbidity. All plans 
consisted of anterior and two lateral fields. 
In case of T3 stage or PSA level higher 
than 20 ng/ml or Gleason score above 7, 
the elective irradiation of pelvic lymph 
nodes to the total dose of 45 Gy was 
introduced. In such cases in first phase 
of treatment four fields (box-technique) 
were used. We have checked the geo-
metry of the irradiated fields by electronic 
portal imaging performed at the start 
of the treatment and than in 10 -day inter-
vals. Examples of dose volume histograms 
(DVHs) of treatment plans for the prostate 
plus seminal vesicles are shown in Figure 
1, and the prostate with seminal vesicles 
and elective pelvic irradiation is represen-
ted in Figure 2. In vivo dosimetry was 
performed for each patient at the begin-
ning and the mid- of treatment. We did not 
observe any significant deviation between 
the planned and measured doses. 
   Acute reactions included those arising 
during  the  irradiation  and  others  within 
Fig. 1. Dose Volume Histograms for the three field technique which encompassed only the prostate and seminal vesicles to the total
dose of 72 Gy.
Fig. 2. Dose Volume Histograms for II phases of treatment (box technigue = 45 Gy and than three fields which encompassed the prostate
and seminal vesicles to total dose of 72 Gy).
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the first 90 days after the completion 
of treatment. Acute toxicities were evalu-
ated using the Radiation Therapy Oncolo-
gy Group (RTOG) morbidity scoring scale 
at weekly evaluations. The median follow-
up was 11 months (range: 6 to 15 months). 
During the follow-up patients were follo-
wed by a radiation oncologist and urologist 
at one month intervals. 
 
RESULTS 
 
   All our patients completed the entire 
course of radiotherapy and were asse-
ssable for evaluation for acute toxicities 
and early biochemical outcome (PSA). 
The most common side effects of andro-
gen ablation were „hot flushes”, gyneco-
mastia, although these were mild. No gaps 
during irradiation were introduced caused 
by acute side effects of the treatment. 
   Grade 1 toxicities involved minimum 
symptoms and required no medication. 
Grade 2 toxicities were slightly more 
severe and required medication. Lopera-
mide was the most commonly prescribed 
drug and nonsteroidal antiflammatory 
drugs such as ibuprofen, diclofenac that 
were used to control GU symptoms. 
The most significant acute adverse effects 
noted in the gastrointestinal tract (GI) were 
nausea, rectal discomfort and mild 
diarrhea (grade 1 or 2). Diarrhea occured 
when the elective pelvic lymph nodes were 
irradiated. Acute rectal side effects were 
observed at the end of treatment. Usually 
after the 4th week of irradiation moderate 
loose-stools/diarrhea occurred and, only 
few patients required short-time (two 
weeks) medication (loperamide). The GI 
toxicity grade 0 and 1 were observed 
in 75% of patients and grade 2 in 25% 
of patients.  
   Acute genitourinary (GU) symptoms 
included increased urgency, nocturia and 
dysuria. The GU toxicities were grade 
0 and 1 (80% of patients) and grade 2 
(20% of patients). The urinary symptoms 
typically appeared during the third week 
of treatment and resolved within a few 
weeks later. 
  No grade 3 or 4 GI and GU toxicities were 
observed. Generally mild relief medication 
(antyinflammatory) was required in 25% 
of patients. We noted that some symptoms 
of early reaction to irradiation may have 
overlapped with some symptoms, which 
occured before treatment. 
 
DISCUSSION 
 
   At present three-dimensional treatment 
planning and conformal irradiation 
(3DCRT) reaplaces 2 dimensional (2D) 
techniques in the treatment of many 
cancers, especially that of the prostate 
cancer [8]. The main advantages of such 
a treatment planning in prostate cancer 
are: use of CT images for better deli-
neation of the target and sourrounding 
organs at risk (rectum, bladder, femoral 
head), and more precise information for 
the more sophisticated computer calcu-
lating systems. In this way radiation dose 
conforms better to the tumour, and that 
is why, the dose to the adjuncet tissue 
decreases, which make it possible to in-
crease the dose to the tumour. On the 
other hand, a normal tissue toxicity is on 
the same level or is even decreased 
[9, 10, 11]. 
   In our paper, early side effects of a com-
bined treatment (androgen ablation the-
rapy and 3D radiotherapy) patients with 
prostate cancer (stage T1-T3 N0M0) were 
evaluated. The data from literature indi-
cate that a combined treatment may lead 
to better results [12]. Example of com-
bined treatment was the trial study con-
ducted by RTOG (RTOG 9202): 
neoadjuvant androgen ablation was intro-
duced 2 months prior to irradiation and 
then was continued during radiotherapy 
and for 2 years after termination of irra-
diation. In a group of patients treated with 
hormonal therapy and radiotherapy 
the 5-year overall survival rate was 80% 
vs. 69% in patients without additional 
hormonotherapy [7]. Another well docu-
mented trial that shown a therapeutic 
benefit was study carried out by Bolla 
et al. [6]. In this study two modalities 
of treatment were compared: radiotherapy 
alone versus radiotherapy plus long-term 
adjuvant hormonotherapy (3 years). 
This study confirmed that combined treat-
ment resulted in an increase of 5 years 
survival from 62% to 79% (p = 0.001). 
The question whether it represents sensi-
tization of the tumor to radiation due 
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to androgen deprivation or constitute 
an additive therapeutic effect, remain 
unresolved. Many studies demonstrated 
statistically significant reductions in the vo-
lume of the irradiated tissue because 
neoadjuvant androgen supression reduced 
the volume of prostate cancer and the vo-
lume of the enlarged prostate gland [13]. 
The tumour volume reduction may also 
result in the improvement of the blood flow 
and decrease in the tumour cell hypoxia. 
According to Zelefsky et al. [5] neo-
adjuvant androgen deprivation seemed 
to have a significant impact on local 
control, and reduced the recurrence rate, 
but did not influence the overall survival. 
These data also indicate that the com-
bined treatment is associated with a higher 
incidence of treatment induced impotence. 
Among the 159 patients who were potent 
(able to maintain a functional erection) 
before treatment, the 2-year actuarial 
incidence of impotence was 43%, 
compared with 27% for 385 patients who 
received radiation alone (p<0,001).  
   Generally, the combined treatment is 
a promising option of treatment because 
offers better results without overlapping 
toxicities [16]. 
   We have defined acute toxicity as side 
effects of treatment which occured during 
the course of irradiation and also 90 days 
after the termination of radiotherapy. This 
definition is generally accepted by radia-
tion oncologistes, but the time factor used 
as the criterion which distinguishes acute 
and late morbidities may reflect the lack 
of knowledge about the real nature of res-
ponse to irradiation in health tissue. In our 
study, the acute toxicity was evaluated 
according to the RTOG morbidity scale. 
The average total dose prescribed 
to the target was 70.2 Gy and this dose 
level in the treatment of patients with 
prostate cancer lies in the middle range 
of dose escalation [17,18]. In each case, 
we kept the total dose below 70 Gy to 30% 
of the rectum volume. Another fact 
is worth to stressing is that the volume 
of the irradiated rectum received only 
a small fraction of the total dose even 
in case the of elective irradiation of the 
pelvic lymph nodes. 
Each patient received androgen depletion 
treatment with LH-RH (goserelin) or bila-
teral orchiectomy plus flutamide. During 
irradiation and follow-up we did not 
observe any additional side effect except 
„hot flushes” and gynecomastia, which are 
typical to hormonal therapy. We have also 
attempted to introduce a questionnaire 
in which we asked each patient about the 
potency defined as a possibility of sexual 
activity. The questionnaire was filled up 
at the beginning the radiotherapy, during 
radiotherapy and during the follow-up. 
Only 10 patients out of 22 were evaluable 
for this questionnaire (11 patients refu-
sed), and no patients did not observe any 
decrease of potency during course of irra-
diation and follow-up. This evaluation has 
not been complete due to a very short time 
of the follow up. It is known, that pro-
gression of the impotence caused by irra-
diation is very slow and even takes years.  
   We have generally, used only small 
fields which encompassed the prostate 
and seminal vesicles leaving out pelvis 
lymph nodes. Only 7 out of 22 patients 
were irradiated using pelvic elective fields 
in first phase of treatment. There is still 
no agreement whether yes or not 
administer elective irradiation of the pelvic 
lymph nodes. According to data from 
literature, introduction an elective 
irradiation of pelvic lymph nodes does not 
change the overall survival rate in patients 
with a localized stage of disease but 
the toxicity of treatment seems to be hig-
her [19,20]. Probably the application 
of the small fields is one of the most 
important factors which was responsible 
for the fact that we did not observe more 
severe GI side effects of our treatment. 
The levels of toxicities from gastro-
intestinal tract (GI) observed in our group 
of patients were in the same range as 
those reported by other authors [21]. Six 
of 22 patients experienced acute grade 
1 GI morbidity. Only 25% of them had 
grade 2 acute toxicity from GI and no pa-
tient required a intensive medical 
treatment. No patients experienced grade 
3 or 4 morbidity. 
   The more pronounced side effects from 
the genitourinary tract (GU) were: nocturia, 
dysuria, increased frequency of urination. 
Only 5 out of 22 patients had grade 1 GU 
toxicity and also 5 out of 22 patients had 
grade 2 GU morbidity. We did not note any 
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GU toxicities higher than grade 2. The sa-
me observations were made by Pilepich 
et al. [22] and by Soffen et al. [23]. These 
investigators applied a higher total dose, 
even up to 78 Gy or 81 Gy. We have 
to emphasize that in the majority of our 
patients we used small fields which 
covered the prostate and seminal vesicles 
and it could have led to an decrease in the 
volume of the irradiated tissue. We did not 
observe more pronunced acute side 
effects because these are more volume-
dependent than dose-dependent [24].   
   We did not try to evaluate early 
biochemical response (PSA) due to small 
number of patients and short time 
of the follow-up [25,26].  
   In this work, we have only evaluated 
early side effects of the combined 
treatment during the course of radio-
therapy, and time of 3 months after 
completion of treatment. The resolvment 
of side effects releated to the radiotherapy 
and the hormonal therapy were done 
at about 3 months of the follow-up. 
   In our opinion, the quality of patient’s life 
even during such a short time in relation 
to overall survival time after treatment 
is important and may influence the deci-
sion making about treatment. 
 
CONCLUSIONS 
 
   Major problems in the use of EBRT 
concerns the risk of developing of radia-
tion proctitis and rectal bleeding. The pre-
liminary results of treatment with a high-
dose 3 D-CRT suggest that such a mo-
dality is well tolerated with only modest 
acute toxicites of GI and GU without 
severe toxicities. Neo-adjuvant therapy 
does not exacerbate radiation included 
toxicity. A longer follow-up is needed 
to evaluate the longer-term tolerance 
of treatment which could seem more 
important both from the patient’s point 
of view and from that of the outcome 
of treatment. 
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